Brooks Laboratories Limited (NSE:BROOKS)

India flag India · Delayed Price · Currency is INR
59.63
+1.17 (2.00%)
Mar 10, 2026, 9:20 AM IST
-48.47%
Market Cap 1.72B
Revenue (ttm) 888.46M
Net Income (ttm) 216.03M
Shares Out 29.46M
EPS (ttm) 7.40
PE Ratio 7.90
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 645
Average Volume 107,044
Open 60.58
Previous Close 58.46
Day's Range 59.63 - 60.84
52-Week Range 57.25 - 164.02
Beta 0.42
RSI 28.65
Earnings Date May 18, 2026

About Brooks Laboratories

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also ... [Read more]

Sector Healthcare
Founded 2002
Employees 323
Stock Exchange National Stock Exchange of India
Ticker Symbol BROOKS
Full Company Profile

Financial Performance

In fiscal year 2025, Brooks Laboratories's revenue was 825.57 million, an increase of 3.86% compared to the previous year's 794.86 million. Losses were -99.67 million, -49.13% less than in 2024.

Financial Statements

News

There is no news available yet.